Literature DB >> 9477953

Release of nontransmembrane full-length Alzheimer's amyloid precursor protein from the lumenar surface of chromaffin granule membranes.

N Tezapsidis1, H C Li, J A Ripellino, S Efthimiopoulos, D Vassilacopoulou, K Sambamurti, T Toneff, S Yasothornsrikul, V Y Hook, N K Robakis.   

Abstract

We previously demonstrated the presence of a soluble form of full-length Alzheimer's amyloid precursor protein (APP) in the lumen of adrenal medullary chromaffin granules (CG). Furthermore, full-length APP is released from CG membranes in vitro at pH 9.0 by an enzymatic mechanism, sensitive to protease inhibitors [Vassilacopoulou et al. (1995) J. Neurochem. 64, 2140-2146]. In this study, we found that when intact CG were subjected to exogenous trypsin, a fraction of APP was not digested, consistent with an intragranular population of APP. To examine the substrate-product relationship between membrane and soluble full-length APP, we labeled CG transmembrane APP with 3-(trifluoromethyl)-3-(m-[125I]iodophenyl)diazirine ([125I]TID), a lipophilic probe, specific for membrane-spanning domains of proteins. APP released from the membranes at pH 9.0 was not labeled with [125I]TID. In addition, this APP was not biotinylated in intact CG. Combined, the results indicate that APP released from CG membranes derives from a unique nontransmembrane population of membrane-associated APP, located in the lumenal side of CG membranes. Dithiobis(succinimidylpropionate) (DSP) cross-linking indicated that APP in CG is situated in close proximity with other proteins, possibly with APP itself. APP complexes were also detected under nonreducing conditions, without DSP cross-linking. These results, combined with our previous studies, indicate that full-length APP within CG exists as three different populations: (I) transmembrane, (II) membrane-associated/nontransmembrane, and (III) soluble. The existence of nontransmembrane populations suggests that putative gamma-secretase cleavage sites of APP, assumed to be buried within the lipid bilayer, could be accessible to proteolysis in a soluble intravesicular environment.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9477953     DOI: 10.1021/bi9714159

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  12 in total

Review 1.  Pharmacogenetic features of cathepsin B inhibitors that improve memory deficit and reduce beta-amyloid related to Alzheimer's disease.

Authors:  Vivian Hook; Gregory Hook; Mark Kindy
Journal:  Biol Chem       Date:  2010-08       Impact factor: 3.915

Review 2.  Protease pathways in peptide neurotransmission and neurodegenerative diseases.

Authors:  Vivian Y H Hook
Journal:  Cell Mol Neurobiol       Date:  2006-05-25       Impact factor: 5.046

Review 3.  Cysteine Cathepsins in the secretory vesicle produce active peptides: Cathepsin L generates peptide neurotransmitters and cathepsin B produces beta-amyloid of Alzheimer's disease.

Authors:  Vivian Hook; Lydiane Funkelstein; Jill Wegrzyn; Steven Bark; Mark Kindy; Gregory Hook
Journal:  Biochim Biophys Acta       Date:  2011-09-08

4.  CSF sAPPα and sAPPβ levels in Alzheimer's Disease and Multiple Other Neurodegenerative Diseases: A Network Meta-Analysis.

Authors:  Wei Tang; Yan Wang; Juan Cheng; Jie Yao; Yu-You Yao; Qiang Zhou; Shi-He Guan
Journal:  Neuromolecular Med       Date:  2019-08-14       Impact factor: 3.843

5.  Beta-amyloid peptides undergo regulated co-secretion with neuropeptide and catecholamine neurotransmitters.

Authors:  Thomas Toneff; Lydiane Funkelstein; Charles Mosier; Armen Abagyan; Michael Ziegler; Vivian Hook
Journal:  Peptides       Date:  2013-06-06       Impact factor: 3.750

6.  Proteomics of dense core secretory vesicles reveal distinct protein categories for secretion of neuroeffectors for cell-cell communication.

Authors:  Jill L Wegrzyn; Steven J Bark; Lydiane Funkelstein; Charles Mosier; Angel Yap; Parsa Kazemi-Esfarjani; Albert R La Spada; Christina Sigurdson; Daniel T O'Connor; Vivian Hook
Journal:  J Proteome Res       Date:  2010-10-01       Impact factor: 4.466

7.  Palmitoylation of the intracytoplasmic R peptide of the transmembrane envelope protein in Moloney murine leukemia virus.

Authors:  K E Olsen; K B Andersen
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

Review 8.  Alternative pathways for production of beta-amyloid peptides of Alzheimer's disease.

Authors:  Vivian Hook; Israel Schechter; Hans-Ulrich Demuth; Gregory Hook
Journal:  Biol Chem       Date:  2008-08       Impact factor: 3.915

9.  Pyroglutamate-amyloid-β and glutaminyl cyclase are colocalized with amyloid-β in secretory vesicles and undergo activity-dependent, regulated secretion.

Authors:  Holger Cynis; Lydiane Funkelstein; Thomas Toneff; Charles Mosier; Michael Ziegler; Birgit Koch; Hans-Ulrich Demuth; Vivian Hook
Journal:  Neurodegener Dis       Date:  2014-06-18       Impact factor: 2.977

Review 10.  Transmembrane Amyloid-Related Proteins in CSF as Potential Biomarkers for Alzheimer's Disease.

Authors:  Inmaculada Lopez-Font; Inmaculada Cuchillo-Ibañez; Aitana Sogorb-Esteve; María-Salud García-Ayllón; Javier Sáez-Valero
Journal:  Front Neurol       Date:  2015-06-02       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.